PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

DWK Life Sciences announces primary packaging supply chain agreement to support vaccine development

DWK Life Sciences has announced a primary packaging supply chain agreement with the VMIC to support vaccine development. The company will be supplying borosilicate pharmaceutical glass vials.

DWK Life Sciences has announced a supply chain agreement with the UK’s Vaccines Manufacturing and Innovation Centre (VMIC) that will see the company provide primary packaging – in the form of borosilicate pharmaceutical glass vials – to the organisation.

VMIC, a not-for-profit organisation, has been established to provide the UK’s first strategic vaccine development and advanced manufacturing capability and has taken a leading role in advising Government teams on vaccines manufacturing in response to COVID-19. With a 7,400 square metre facility due to open in 2021 VMIC will work with partners ranging from SMEs to multinationals as well as academic and research partners, to manufacture vaccines for a wide range of diseases and provide national emergency response in pandemic situations.

DWK will begin manufacturing vials that will be used by VMIC and its partners to ensure finished vaccines can be quickly transported to front line health services when they are available.

To prepare for the potential of further orders in this area, DWK Life Sciences is looking to make additional investment at its manufacturing plant, which is located in Stoke-on-Trent in the United Kingdom. The site is the only remaining UK based production facility capable of producing glass vials for the pharmaceutical industry. While the company still has capacity available owing to previous and ongoing investment, it is actively exploring funding options that will enable a further increase in production capability.

Gareth Rowlands, CEO at DWK Life Sciences Limited, said: “This is a tremendous development for our business. We will be working hard to ensure the benefits of vaccine breakthroughs linked to VMIC’s work can be fully realised and delivered to front line health services as quickly as possible as a result of a robust primary packaging supply chain.

“This will involve an immediate acceleration in capacity at our Stoke-on-Trent site and plans for future expansion, ensuring we are well placed to meet any ramp up in the future.”

Chris Lucas, Chief Operating Officer at the Vaccines Manufacturing and Innovation Centre, said: “It’s crucial that we have a robust supply chain in place for when we are fully operational in 2021 and this agreement with DWK Life Sciences shores up a proportion of the vials VMIC will need.

“I’m delighted that a UK company has been secured as part of this procurement process – growing the vaccines supply chain in the UK is vitally important if we are to have sovereign resilience in the long-term.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026